In this episode of Lipid Leaders, Dr. Robert Hegele speaks with Dr. Ruth McPherson, MD, PhD, FRCPC, FACP, FRSC, Director of the Ruddy Canadian Cardiovascular Genetics Centre, Atherogenomics Laboratory and the Lipid Clinic at the University of Ottawa Heart Institute.
We’re delighted to announce the launch of Lipid Leaders, a new feature of the VESL community where we highlight the important work of researchers in the Canadian lipid and cardiovascular community.
In the first edition of Lipid Leaders, Dr. Samer Mansour speaks with Dr. Jacques Genest, MD, FRCP(C),gaining personal insights into his remarkable journey in research. Dr. Genest is a professor of Medicine at McGill University and staff Cardiologist at the McGill University Health Centre.
We’re pleased to announce the launch of a new initiative called VESL (Virtual Engagement Social Learning), an online learning community for Canadian healthcare professionals with an interest in atherosclerotic cardiovascular disease.
VESL will foster open scientific discussions through online forums, webinars and micro-learning objects, to sustain ongoing connection anchored in scientific discovery and expert insight. It is our hope that this enhanced collaboration will advance understanding in this field and support the highest level of care for patients in Canada.
Members of VESL will receive a weekly email digest with a summary of newly-released scientific articles from VESL members, curated content from sources identified by the VESL faculty, as well as periodic learning opportunities including structured questions to initiate forum discussions, and polling questions to augment community discussions.
LegitiMed will be managing this virtual community residing on Sosido (www.sosido.com).
We are interested in a full exchange of ideas around this subject. So, if you know others who would be interested in participating in the VESL community, we welcome your referrals/recommendations.
We thank Novartis Canada for their support of this initiative.
The VESL community is designed for the scientific exchange of information between Healthcare Professionals and is made possible with financial support from Novartis Canada. Novartis does not itself monitor the discussions. However, a third-party service provider does review the discussions only for the purpose of identifying any potential AE discussion. This review is required since as a drug manufacturer, Novartis has a regulatory obligation to report any AE that (directly or indirectly) comes to their attention. The third-party will only report the potential AE discussion and will include contact information. Should your post be reported to patient safety, you will be contacted by the third-party service provider to determine if you would like Novartis patient safety to contact you for more details.